Big Tobacco Wins—FDA Independence CRUSHED

(LibertySociety.com) – President Trump has approved a plan to oust FDA Commissioner Marty Makary just over a year into his tenure, exposing deep fractures within the administration over drug approvals and vaping regulations that Americans deserve to understand.

Story Highlights

Trump signed off on firing FDA Commissioner Marty Makary after clashes over flavored e-cigarette approvals and pharmaceutical industry disputes
Makary resisted White House pressure to fast-track vaping products following Trump’s meeting with R.J. Reynolds executives in May 2026
The embattled commissioner remains in office as of May 11 with no execution date set, though Trump publicly denied knowledge of any removal plan
Internal FDA turmoil includes deputy commissioner’s recent resignation and pharmaceutical sector frustration over unexpected drug rejections

White House-FDA Tensions Reach Breaking Point

The Wall Street Journal first reported on May 8, 2026, that President Trump approved a plan to terminate FDA Commissioner Marty Makary, a Johns Hopkins surgeon who took office in March 2025. Multiple sources confirmed the decision stems primarily from Makary’s resistance to approving fruit-flavored e-cigarettes, which Trump personally pressured him to greenlight following a White House meeting with R.J. Reynolds executives. The FDA ultimately approved the flavored vaping products on May 6, but the damage was done. When confronted by reporters on May 9, Trump denied any knowledge of the firing plan, stating “Know nothing about it” and responding “No, no” when asked about selecting a new FDA chief.

Pattern of Industry Pressure Over Scientific Independence

This episode reveals a troubling dynamic where corporate interests appear to supersede the FDA’s mandate to protect public health based on scientific evidence. The vaping industry has long sought approval for flavored products, which public health advocates link to youth nicotine addiction. Makary’s initial resistance represented standard regulatory caution, yet direct intervention from the Oval Office forced capitulation. Beyond vaping, pharmaceutical companies have reportedly complained to White House advisers about Makary blocking their agenda, particularly after unexpected rejections like Replimune’s RP1 melanoma therapy. Deputy Commissioner Vinay Prasad, who co-authored decisions with Makary that angered the biopharma sector, resigned last week amid the mounting pressure.

Uncertain Timeline Creates Regulatory Paralysis

As of May 11, Makary remains FDA Commissioner with no firm termination date, creating what Axios characterized as a “cliffhanger” situation. Trump’s approval of the firing plan does not guarantee execution; the president has historically reversed personnel decisions on a whim. Politico reported that Makary believed his position was secure until the rapid shift following the vaping industry meeting. This uncertainty paralyzes the FDA at a critical moment, stalling decisions on pending drug applications and leaving pharmaceutical companies unable to plan. The agency’s website continues to list Makary as commissioner, yet potential successors including deputy Kyle Dantas and Trump administration veterans Stephen Hahn and Brett Pritt are reportedly under consideration as “conventional” replacements who might prove more amenable to industry demands.

Broader Implications for Agency Independence

The Makary saga exposes fundamental questions about whether regulatory agencies can function independently when corporate lobbyists have direct access to presidential decision-making. The FDA’s authority rests on its reputation for science-based evaluations free from political interference, a principle dating to reforms following pharmaceutical disasters decades ago. Trump’s hands-on involvement in approval decisions for specific consumer products represents a departure from traditional executive restraint, regardless of whether one supports faster approvals or more cautious regulation. Both conservatives frustrated with bureaucratic obstacles to innovation and liberals concerned about corporate capture of government have reason to question whether the FDA serves the American people or well-connected industries. The timing proves particularly concerning given Robert F. Kennedy Jr.’s influence as HHS Secretary, adding another layer of unconventional health policy direction that will shape drug safety, food regulation, and public trust for years beyond this administration.

The lack of official White House confirmation or formal termination leaves Americans in limbo about who truly runs the FDA and what standards will govern the approval of drugs and consumer products they depend on daily. This situation underscores a reality both political sides increasingly recognize: when government decisions appear driven by which industries have the president’s ear rather than transparent processes accountable to citizens, the system fails everyone except those wealthy enough to schedule Oval Office meetings. Whether Makary ultimately departs or survives this episode, the message to future FDA leaders is clear—scientific independence may be subordinate to political and corporate preferences in this administration.